About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The Psychiatry, Mental Health and Addictions Research Group at the Vall d'Hebron Research Institute is a multidisciplinary team that over the past 13 years has focused its scientific activity on the research (both nationally and internationally) of clinical, therapeutic and etiopathogenic aspects of:
At international level, it participates and/or coordinates several European projects of great repercussion in the area of mental health. At national level, it is part of the CIBERSAM (Centre for Biomedical Research in Mental Health Network) together with other leading groups, conducting research of excellence.
IP: José Antonio Ramos Quiroga
IP: Francisco Collazos Sanchez
IP: Francisco Collazos Sanchez Collaborators: Mar Ramos Gascon, Hanaa Boudoukhan Benriyyan Funding agency: Fundació "La Caixa" Funding: 30000 Reference: CY23-00771 Duration: 29/07/2024 - 29/07/2025
IP: Maria Soler Artigas Collaborators: Pau Carabí Gassol, Miriam Izquierdo Sans Funding agency: Instituto de Salud Carlos III Funding: 119567 Reference: FI23/00152 Duration: 15/01/2024 - 14/01/2027
IP: Marta Ribases Haro Collaborators: Montserrat Corrales De la Cruz, Judit Cabana Dominguez, Laura Gisbert Gustemps, Gemma Español Martín, Vanesa Richarte Fernández, Christian Fadeuilhe Grau Funding agency: Instituto de Salud Carlos III Funding: 131250 Reference: PI23/00404 Duration: 01/01/2024 - 31/12/2026
IP: Maia Brik Spinelli Collaborators: Miguel Angel Sandonis Vicente, Nerea Maiz Elizaran, Gemma Parramon Puig, Elena Carreras Moratonas Funding agency: Ministerio de Ciencia e Innovación-MICINN Funding: 115315 Reference: CPP2022-009996 Duration: 01/12/2023 - 30/11/2026
PhD student: Raul Felipe Palma Alvarez Director/s: Carlos Roncero Alonso, Lara Grau Lopez University: Universitat Autònoma de Barcelona Year: 2022
PhD student: Christian Fadeuilhe Grau Director/s: José Antonio Ramos Quiroga, Lara Grau Lopez, Constanza Daigre Blanco University: Universitat Autònoma de Barcelona Year: 2022
Over the course of one week, it will host in-person assessments for 35 families to better understand the progression of the disease and contribute to the development of new therapies.
A project led by the Vall d’Hebron Research Institute (VHIR) in collaboration with FIDMAG Germanes Hospitalàries Research Foundation describes structural and functional brain changes in adolescents with borderline personality disorder (BPD).
A large-scale study involving Vall d’Hebron confirms the genetic relatedness among 14 different psychiatric disorders and groups them into five new families, paving the way for new treatments targeting their shared underlying genetic causes
